Project Details
Description
Project summary/abstract
Carbapenem-resistant Klebsiella pneumoniae (Kp) strains belonging to sequence type (ST) 258 have spread
globally in the past decades. Their association with often-fatal ventilator-associated pneumonia is of urgent public
health concern especially in light of the current COVID-19 pandemic. While numerous studies have focused on
investigating antimicrobial resistance strategies, there is still a lack of effective therapeutic agents, which urges
the need to better understand other factors that are crucial for Kp ST258 persistence. Kp ST258 strains differ
from hypervirulent strains that induce rapidly fatal infections by instead causing subacute chronic infections.
Failure to clear Kp ST258 is associated with the recruitment of monocytes (myeloid-derived suppressor cells,
MDSCs) with anti-inflammatory properties similar to those that promote the growth of tumor cells during
oncogenesis. Given that metabolic activities govern the function of immune cells, we hypothesize that Kp ST258
metabolism in a manner similar to tumor metabolism generates host metabolic stress and a milieu conducive to
the generation and expansion of immunosuppressive cells. We found that Kp ST258 stimulates a unique host
metabolic response during pulmonary infection that is characterized by the rapid depletion of glucose, stimulation
of glutaminolysis and fatty acid oxidation (FAO) pathways that fuel oxidative phosphorylation (OXPHOS) and
reactive oxygen species (ROS) production, and the accumulation of the antioxidative metabolite itaconate. This
project offers a novel approach to develop therapeutic strategies drawing upon the host metabolic response to
Kp ST258 as the main factor promoting chronic pulmonary infection. Specifically, aim 1 explores the dynamics
of the host immunometabolic response to Kp ST258. Aim 2 seeks to investigate how this response promotes
immunosuppression while aim 3 focuses on its direct effect on bacterial adaptation to and survival in the airway
by driving global changes in bacterial gene expression including the upregulation of the Type Six Secretion
System (T6SS) to counteract oxidative stress.
Status | Finished |
---|---|
Effective start/end date | 4/1/22 → 3/31/23 |
Funding
- National Heart, Lung, and Blood Institute: US$122,151.00
ASJC Scopus Subject Areas
- Infectious Diseases
- Pulmonary and Respiratory Medicine
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.